drugset / Trial / NCT06255262
Durvalumab Combined With Surufatinib as Maintenance Therapy in Patients With Advanced Biliary Tract Cancer
NaSingle-groupOpen-labelTreatment
Summary
A Real-World Study of Durvalumab combined with Surufatinib as maintenance therapy in patients with advanced biliary tract cancer whose disease did not progress after completion of first-line Durvalumab combined with Gemcitabine+cisplatin treatment.
Timeline
- Start
- 2024-02-15
- Primary completion
- 2025-10-31
- Completion
- 2025-12-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Durvalumab | Monoclonal antibody | 1500 mg | Intravenous |
| Subject | Surufatinib | Small molecule | 200 mg | Oral |
| Subject | Surufatinib | Small molecule | 250 mg | Oral |